Quarterly ResultMay 14, 2026, 02:08 PM
Monopar Q1 Net Loss $(3.89)M; EPS $(0.46)
AI Summary
Monopar Therapeutics reported a net loss of $(3.89) million, or $(0.46) per share, for the three months ended March 31, 2026, compared to a net loss of $(2.62) million, or $(0.38) per share, in the prior year period. The company's cash and cash equivalents decreased to $52.54 million from $61.83 million at year-end 2025. Despite a pivotal Phase 3 trial meeting its primary endpoint, Alexion terminated the ALXN1840 program for Wilson disease, leading Monopar to focus on submitting an NDA with uncertain outcomes. Management projects current cash will fund operations through December 31, 2027.
Key Highlights
- Net loss for Q1 2026 was $(3.89) million, up from $(2.62) million in Q1 2025.
- Basic and diluted EPS was $(0.46) in Q1 2026, compared to $(0.38) in Q1 2025.
- Research and development expenses increased to $3.49 million in Q1 2026 from $1.64 million in Q1 2025.
- Cash and cash equivalents stood at $52.54 million as of March 31, 2026, down from $61.83 million.
- Accumulated deficit reached approximately $93.4 million as of March 31, 2026.
- ALXN1840 program for Wilson disease was terminated by Alexion despite Phase 3 success.
- Management expects current cash to fund operations through December 31, 2027.
Price Impact
More from MNPR